US Stock MarketDetailed Quotes
CANF Can-Fite BioPharma
- 2.2326
- +0.0726+3.36%
Trading Nov 4 14:07 ET
13.61MMarket Cap-859P/E (TTM)
2.5000High2.0700Low113.06KVolume2.0700Open2.1600Pre Close254.62KTurnover1.86%Turnover RatioLossP/E (Static)6.10MShares4.690052wk High5.49P/B13.61MFloat Cap1.830052wk Low--Dividend TTM6.10MShs Float1419.0000Historical High--Div YieldTTM19.91%Amplitude1.5200Historical Low2.2520Avg Price1Lot Size
Can-Fite BioPharma Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (FY)Dec 31, 2022 | (FY)Dec 31, 2021 | (FY)Dec 31, 2020 | (FY)Dec 31, 2019 | (FY)Dec 31, 2018 | (FY)Dec 31, 2017 | (FY)Dec 31, 2016 | (FY)Dec 31, 2015 | (FY)Dec 31, 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 21.86%-8.44M | -9.57%-10.8M | 18.28%-9.86M | -8.83%-12.06M | -166.76%-11.08M | 53.69%-4.16M | -2.96%-8.97M | -87.33%-8.71M | 36.51%-4.65M | 15.10%-7.33M |
| Net income from continuing operations | 24.96%-7.63M | 19.36%-10.17M | 12.66%-12.62M | -14.40%-14.44M | -92.13%-12.63M | -2.15%-6.57M | 23.35%-6.43M | -65.72%-8.39M | 19.59%-5.06M | 28.82%-6.3M |
| Operating gains losses | ---- | ---- | ---- | ---- | ---- | 111.74%89K | -150.99%-758K | -1,354.15%-302K | -88.02%24.08K | 223.94%201.08K |
| Depreciation and amortization | 7.14%15K | 0.00%14K | 16.67%14K | -14.29%12K | 0.00%14K | -26.32%14K | 5.56%19K | 9.79%18K | 35.83%16.39K | -27.53%12.07K |
| Other non cash items | -296.46%-222K | 345.65%113K | -300.00%-46K | 1,250.00%23K | ---2K | ---- | ---- | ---- | -337.24%-1.23M | -147.27%-280.69K |
| Change In working capital | 27.52%-943K | -153.54%-1.3M | 21.99%2.43M | 113.05%1.99M | -17.55%935K | 156.79%1.13M | -477.17%-2M | -123.28%-346K | 254.54%1.49M | -316.06%-961.75K |
| -Change in receivables | ---- | ---- | ---- | ---- | ---- | 70.66%-853K | -108.09%-2.91M | -647.53%-1.4M | 184.13%255.15K | -90.31%-303.29K |
| -Change in prepaid assets | 176.35%184K | -288.28%-241K | -97.01%128K | 1,834.39%4.28M | --221K | ---- | ---- | ---- | ---- | ---- |
| -Change in payables and accrued expense | -59.57%-300K | -119.44%-188K | 151.60%967K | -427.05%-1.87M | -25.49%573K | -35.86%769K | 67.46%1.2M | 807.47%716K | 111.98%78.9K | -817.24%-658.46K |
| -Change in other current assets | ---- | ---- | ---- | ---- | --28K | --0 | ---- | ---- | ---- | ---- |
| -Change in other current liabilities | -35.48%-84K | 1.59%-62K | -687.50%-63K | 75.76%-8K | ---33K | --0 | ---- | ---- | ---- | ---- |
| -Change in other working capital | 8.27%-743K | -157.94%-810K | 448.63%1.4M | -374.66%-401K | -88.01%146K | 521.45%1.22M | -186.27%-289K | -70.93%335K | --1.15M | ---- |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 21.86%-8.44M | -9.57%-10.8M | 18.28%-9.86M | -8.83%-12.06M | -166.76%-11.08M | 53.69%-4.16M | -2.96%-8.97M | -87.33%-8.71M | 36.51%-4.65M | 15.10%-7.33M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -94.76%498K | 165.48%9.5M | -55,711.54%-14.51M | -766.67%-26K | 90.91%-3K | -13.79%-33K | -190.00%-29K | 76.62%-10K | -350.23%-42.78K | 8.08%-9.5K |
| Net PPE purchase and sale | 77.78%-2K | 18.18%-9K | 57.69%-11K | -766.67%-26K | 90.91%-3K | -371.43%-33K | 30.00%-7K | 76.62%-10K | -350.23%-42.78K | 8.08%-9.5K |
| Net business purchase and sale | ---- | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Net investment purchase and sale | -94.74%500K | 165.59%9.51M | ---14.5M | --0 | --0 | ---- | ---22K | --0 | --0 | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -94.76%498K | 165.48%9.5M | -55,711.54%-14.51M | -766.67%-26K | 90.91%-3K | -13.79%-33K | -190.00%-29K | 76.62%-10K | -350.23%-42.78K | 8.08%-9.5K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 9.14M | 0 | 15.69%20.46M | 73.93%17.68M | 131.75%10.17M | -1.94%4.39M | 4.47M | 0 | 7.92%12.38M | -13.18%11.47M |
| Net issuance payments of debt | ---- | ---- | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- |
| Net common stock issuance | --9.14M | --0 | 15.69%20.46M | 73.93%17.68M | 131.75%10.17M | -1.94%4.39M | --4.47M | --0 | 7.92%12.38M | -12.94%11.47M |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | --9.14M | --0 | 15.69%20.46M | 73.93%17.68M | 131.75%10.17M | -1.94%4.39M | --4.47M | --0 | 7.92%12.38M | -13.18%11.47M |
| Net cash flow | ||||||||||
| Beginning cash position | -32.16%2.98M | -46.90%4.39M | 206.56%8.27M | -25.39%2.7M | 3.14%3.62M | -56.81%3.51M | -52.04%8.12M | 83.02%16.92M | 73.36%9.25M | 334.15%5.33M |
| Current changes in cash | 192.53%1.2M | 66.79%-1.3M | -169.93%-3.91M | 708.04%5.59M | -562.31%-920K | 104.40%199K | 48.11%-4.53M | -213.49%-8.72M | 85.85%7.69M | -9.58%4.14M |
| Effect of exchange rate changes | 186.73%98K | -432.35%-113K | 247.83%34K | -1,250.00%-23K | 102.25%2K | -7.23%-89K | -1.22%-83K | -338.49%-82K | 90.69%-18.7K | -225.11%-200.83K |
| End cash Position | 43.65%4.28M | -32.16%2.98M | -46.90%4.39M | 206.56%8.27M | -25.39%2.7M | 3.14%3.62M | -56.81%3.51M | -52.02%8.12M | 82.49%16.91M | 55.43%9.27M |
| Free cash flow | 21.91%-8.44M | -9.53%-10.81M | 18.36%-9.87M | -9.04%-12.09M | -164.73%-11.09M | 53.36%-4.19M | -2.92%-8.98M | -85.73%-8.72M | 35.98%-4.7M | 15.11%-7.34M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | Unqualified Opinion | Unqualified Opinion | Unqualified Opinion | Unqualified Opinion | Unqualified Opinion | Unqualified Opinion | Unqualified Opinion | Unqualified Opinion | Unqualified Opinion |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data